For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...

Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous (SC) induction therapy in patients with moderately to severely active ulcerative colitis (UC). Study participants ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis: Spring House, Pennsylvania Mo ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

US healthcare giant Johnson & Johnson has announced data from the Phase III ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ...

The CoTikiS trial’s ten-week results from the 50-week trial saw as an endoscopic improvement rate of 32% in patients.

Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...